Status and phase
Conditions
Treatments
About
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
49 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Alnylam Clinical Trial Information Line; Alnylam Clinical Trial Information Line
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal